Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference

A correction from Tryp Therapeutics Inc. is being issued for the news release disseminated earlier today. The correction relates to an error in the presentation date and the disclosure of stock option grants. The presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. EDT. No other material changes were required in the body of the release.

San Diego, California--(Newsfile Corp. - September 1, 2021) -  Tryp Therapeutics^[1] (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the H.C. Wainwright 23^rd Annual Global Investment Conference.

The conference will be held virtually on September 13-15, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN^TM) program for chronic pain and other indications.

Registration for the conference can be accessed here^[2]. Tryp's presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. EDT.

Tryp also announces that it has granted an aggregate of 1,200,000 stock options (the "Options") to two members of its Board of Directors. The Options have an exercise price of $0.75 per share, are exercisable until August 31, 2031 (subject to vesting restrictions), and will be governed in accordance with the terms of the Company's stock option plan.

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Inquiries:Joe GreenEdison Groupinvestors@tryptherapeutics.com^[3]

Media Inquiries:Joy WillisTryp Therapeuticsmedia@tryptherapeutics.com^[4]1-833-811-8797

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans," "targets," "expects" or "does not expect," "is expected," "an opportunity exists," "is positioned," "estimates," "intends," "assumes," "anticipates" or "does not anticipate" or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," "will" or "will be taken," "occur" or "be achieved." In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95159^[5]

References

1. ^{^} Tryp Therapeutics (www.newsfilecorp.com)
2. ^{^} here (www.newsfilecorp.com)
3. ^{^} investors@tryptherapeutics.com (www.newsfilecorp.com)
4. ^{^} media@tryptherapeutics.com (www.newsfilecorp.com)
5. ^{^} https://www.newsfilecorp.com/release/95159 (www.newsfilecorp.com)